Steven Cohen’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Steven Cohen’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-201,700	Closed	-$4.42M	–	1198
2017 Q4	$4.42M	Buy	201,700 +138,718	+220%	+$4.46M	0.02%	619
2017 Q3	$2.58M	Buy	+62,982	New	+$1.98M	0.01%	647
2017 Q2	–	Sell	-19,569	Closed	-$707K	–	1064
2017 Q1	$707K	Buy	+19,569	New	+$863K	﹤0.01%	758
2016 Q3	–	Sell	-19,200	Closed	-$794K	–	904
2016 Q2	$794K	Buy	+19,200	New	+$835K	0.01%	641
2015 Q4	–	Sell	-4,600	Closed	-$71K	–	897
2015 Q3	$71K	Sell	4,600 -474,811	-99%	-$10.2M	﹤0.01%	714
2015 Q2	$11.9M	Sell	479,411 -545,289	-53%	-$12.1M	0.08%	289
2015 Q1	$23.4M	Buy	1,024,700 +457,300	+81%	+$11.5M	0.16%	179
2014 Q4	$15.3M	Buy	+567,400	New	+$9.77M	0.11%	256

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Steven Cohen's FPRX Position: Q1 2018 in Review

Steven Cohen sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2018, closing a stake of 201,700 shares — an estimated $4.42M sold.

Steven Cohen first reported a position in FPRX in Q4 2014 and held it in 8 quarters. The position peaked at $23.4M in Q1 2015. 128 funds tracked by Wall St. Rank hold FPRX as of Q1 2018.

Steven Cohen reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Steven Cohen sold 201,700 Five Prime Therapeutics, Inc. shares in Q1 2018, an estimated $4.42M.
Steven Cohen first reported a position in Five Prime Therapeutics, Inc. in Q4 2014 and held it in 8 quarters.
Steven Cohen's Five Prime Therapeutics, Inc. position peaked at $23.4M in Q1 2015.
128 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2018.

Based on Point72 Asset Management's 13F filing for Q1 2018, filed 15 May 2018.